tbuckley/cabot-search huggingface dataset:
Diagnostic capability of multiparametric MRI in patients with transrectal prostate biopsy.
Authors: Jaime Antonio Altamirano, Ivan Federico Pinto, Roberto Mauricio Vilches, Jorge Gonzalo Diaz, Camilo Sandoval, Alvaro Daniel Vidal, Mauricio Canals, Cristobal Roman, Alejandro Rojas, Maria Jesus Quiroz, Andres Vega
Journal: Journal of Clinical Oncology (2016)

155 Background: The prostatic multiparametric MRI (mpMRI) is the combination of anatomical imaging and functional sequences. Nowadays this technique is still being researched due to its positive published results. The objective of this study is to show our experience in the application of the mpMRI in patients, prior to the TRUS-guided biopsy, and the sensitivity and specificity of its measured parameters and their combination. Methods: Prospective cohort. MpMRI was indicated to patients prior to the TRUS-Guided biopsy. Diffusion, PIRADS, DCE and T2 parameters were observed on the MRIs, and the presence of cancer and Gleason score on the biopsy. Logistic regression test was performed with a 95% confidence interval. We assigned different values, depending of the importance of each factor, applying binominal regression. Results: We registered 73 patients with mpMRI prior to the TRUS-Guided Biopsy, and their results. The cancer detection rate was 60.27% (44 patients). The T2 signal had a sensibility of 81.82% and a specificity of 27.59%, ROC curve 0.54 (CI 0.44 – 0.64). The diffusion has a sensibility of 30% and a specificity of 85.19% with a ROC curve of 0.58 (CI 0.48-0.68). The DCE has a sensibility and specificity of 77.78% and 35.29% respectively, ROC curve of 0.57 (CI 0.42-0.71). By combining the T2, diffusion and DCE parameters, having 2 or more altered values, we obtained a sensibility of 84.62% with a 41.18% specificity, curve of 0.68 (CI 0.54-0.81). The sensitivity and specificity with a PIRADS score ≥ 3 was of 68.42 and 36.36% with a ROC curve of 0.56 (CI 0.36-0.76). With a PIRADS ≥ 4 the sensitivity and specificity was 57.89% and 54.55% respectively. The calculated measured score was assigned as 7 points for altered T2, 8 points for altered diffusion and 5 points for altered DCE. With a total value ≥ 12 the sensitivity of the score was 84.62% with a 41.18% sensitivity, ROC curve 0.68 (CI 0.54-0.81). Conclusions: The use of isolated mpMRI parameters have low performance, whereas this is greatly increased when used combined. The assigned weight of each parameter is a factor to consider and review on the existing scores.
“CARDIOVASCULAR and Metabolic Complications in Patients with Hematological Malignancies Undergoing Allogeneic Hematopoietic STEM CELL Transplantation (HSCT)”
Authors: Eleonora Arboscello, Vera Sicbaldi, Federica Galaverna, Fabio Guolo, Paolo Spallarossa, Martina Giovannini, Danilo Baccino, Maria Teresa Van Lint, Matteo Sarocchi, Andrea Bellodi, Lisette Del Corso, Serena Favorini, Elisa Molinari, Jacopo Agnelli Giacchello, Chiara Salvetti, Riccardo Ghio, Andrea Bacigalupo
Journal: Blood (2014)
FCGR3A-158V/F Polymorphism May Correlate with the Levels of Immunoglobulin in Patients with Non-Hodgkin’s Lymphoma after Rituximab Treatment as An Adjuvant to Autologous Stem Cell Transplantation.
Authors: Mitsufumi Nishio, Tomoyuki Endo, Katsuya Fujimoto, Satoshi Yamamoto, Masato Obara, Keisuke Yamaguchi, Yukari Takeda, Hideki Goto, Ikumi Kasahara, Norihiro Sato, Takao Koike
Journal: Blood (2008)
First-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) by gefitinib
Authors: V. Moiseyenko, S. A. Procenko, E. V. Levchenko, A. S. Barchuk, D. E. Matsko, F. V. Moiseyenko, A. O. Ivantsov, A. G. Iyevleva, N. V. Mitiushkina, E. N. Imyanitov
Journal: Journal of Clinical Oncology (2009)

e19088 Background: Gefitinib shows outstandingly high rates of clinical benefit in NSCLC pts with EGFR mutation and is better tolerable than conventional chemotherapy, therefore its consideration for the upfront treatment is warranted. Methods: 21 chemonaive pts with inoperable NSCLC were selected based on the presence of EGFR mutation in the tumor DNA (16 exon 19 deletions and 5 T858G substitutions). All cases were adenocarcinomas; median age: 60 years (range: 36 - 81 years); males/females: 6/15; ECOG PS 0/1/2/3: 4/10/6/1. Gefitinib was administered at conventional dose 250 mg/d. Results: The overall disease control rate was 95% (CR: 2/21; PR: 11/21; SD: 7/21). Complete responses were observed only in tumors with exon 19 deletion, whereas the only patient with disease progression had codon 858 substitution. Grade III toxicity occurred only in 3 pts (2: skin rash; 1: diarrhea). Time to disease progression ranged from 2+ to 18 months. 3 pts achieved an operable status of the disease upon the treatment, and therefore were subjected to surgical intervention followed by adjuvant gefitinib therapy. Conclusions: Gefitinib may be considered as the treatment of choice for chemonaive EGFR mutation-containing inoperable NSCLC. No significant financial relationships to disclose.
Reduced-Intensity Unrelated Cord Blood Transplantation (RICBT) for Elderly Patients with Hematological Malignancies
Authors: Yoshiki Nakae, Rie Kojima, Aki Chizuka, Yuko Osajima, Toshiyuki Noguchi, Kou Miyamoto, Masatsugu Oota, Shigesaburo Miyakoshi
Journal: Blood (2010)
AK2 Regulates Hematopoietic Cell Survival, Proliferation and Differentiation Along the T-Cell and Neutrophil Lineages
Authors: Emmanuelle M. Six, Chantal Lagresle-Peyrou, Corinne Demerens-de Chappedelaine, Justine Trimouillas, Frédéric Rieux-Laucat, Bruno Cassinat, Christine Chomienne, Alain Fischer, Marina Cavazzana-Calvo
Journal: Blood (2011)
Effect of Ruxolitinib On the Incidence of Splenectomy in Patients with Myelofibrosis: A Retrospective Analysis of Data From Ruxolitinib Clinical Trials.
Authors: Srdan Verstovsek, Jean-Jacques Kiladjian, Ruben A. Mesa, Alessandro M. Vannucchi, Jason Gotlib, Giovanni Barosi, Hagop M. Kantarjian, Andres Sirulnik, Wei Peng, Victor A. Sandor, Claire N Harrison
Journal: Blood (2012)
The Immunologic Composition of the Bone Marrow Changes Rapidly During the Harvest Procedure
Authors: Martin Wermke, Cathrin Wegner, Malte von Bonin, Sebastian Tuve, Claudia Schönefeldt, Kristina Hölig, Uta Oelschlegel, Martin Bornhaeuser, Uwe Platzbecker, Rainer Ordemann
Journal: Blood (2012)
Interference with Inflammation Induced Endothelial Receptors Prevents Acute Graft-Versus-Host Disease.
Authors: Andreas Beilhack, Jeanette Baker, Christian Brede, Simone S Riedel, Carina A Baeuerlein, Carolin Kiesel, Ana-Laura Jordan Garrote, Rossella Monteforte, Miriam Ritz, Marina Grether, Georg F Beilhack, Paul G. Schlegel, Hermann Einsele, Robert Negrin, Stephan Schulz
Journal: Blood (2009)
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
Authors: Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Rodrigo Goncalves, Souzan Sanati, Chad J. Creighton, Katherine DeSchryver, Erika Crouch, Amy Brink, Mark Watson, Jingqin Luo, Yu Tao, Michael Barnes, Mitchell Dowsett, G. Thomas Budd, Eric Winer, Paula Silverman, Laura Esserman, Lisa Carey, Cynthia X. Ma, Gary Unzeitig, Timothy Pluard, Pat Whitworth, Gildy Babiera, J. Michael Guenther, Zoneddy Dayao, David Ota, Marilyn Leitch, John A. Olson, D. Craig Allred, Kelly Hunt
Journal: Journal of Clinical Oncology (2017)

Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) –positive primary breast cancer triaged to chemotherapy when the protein encoded by the MKI67 gene (Ki67) level was &gt; 10% after 2 to 4 weeks of neoadjuvant aromatase inhibitor (AI) therapy. A second objective was to examine risk of relapse using the Ki67-based Preoperative Endocrine Prognostic Index (PEPI). Methods The American College of Surgeons Oncology Group (ACOSOG) Z1031A trial enrolled postmenopausal women with stage II or III ER-positive (Allred score, 6 to 8) breast cancer whose treatment was randomly assigned to neoadjuvant AI therapy with anastrozole, exemestane, or letrozole. For the trial ACOSOG Z1031B, the protocol was amended to include a tumor Ki67 determination after 2 to 4 weeks of AI. If the Ki67 was &gt; 10%, patients were switched to neoadjuvant chemotherapy. A pCR rate of &gt; 20% was the predefined efficacy threshold. In patients who completed neoadjuvant AI, stratified Cox modeling was used to assess whether time to recurrence differed by PEPI = 0 score (T1 or T2, N0, Ki67 &lt; 2.7%, ER Allred &gt; 2) versus PEPI &gt; 0 disease. Results Only two of the 35 patients in ACOSOG Z1031B who were switched to neoadjuvant chemotherapy experienced a pCR (5.7%; 95% CI, 0.7% to 19.1%). After 5.5 years of median follow-up, four (3.7%) of the 109 patients with a PEPI = 0 score relapsed versus 49 (14.4%) of 341 of patients with PEPI &gt; 0 (recurrence hazard ratio [PEPI = 0 v PEPI &gt; 0], 0.27; P = .014; 95% CI, 0.092 to 0.764). Conclusion Chemotherapy efficacy was lower than expected in ER-positive tumors exhibiting AI-resistant proliferation. The optimal therapy for these patients should be further investigated. For patients with PEPI = 0 disease, the relapse risk over 5 years was only 3.6% without chemotherapy, supporting the study of adjuvant endocrine monotherapy in this group. These Ki67 and PEPI triage approaches are being definitively studied in the ALTERNATE trial (Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment in Postmenopausal Women: A Phase III Study; clinical trial information: NCT01953588).
Coronary Plaque Burden and Adverse Plaque Characteristics Are Increased in Healthy Relatives of Patients With Early Onset Coronary Artery Disease
Authors: Morten K. Christiansen, Jesper M. Jensen, Bjarne L. Nørgaard, Damini Dey, Hans Erik Bøtker, Henrik K. Jensen
Journal: JACC. Cardiovascular imaging (2017)
Allogeneic Hematopoietic Stem Cell Transplantation in T-Cell Non-Hodgkin Lymphoma.
Authors: Frederico L. Dulley, Daniel Sturaro, Milton A. Ruiz, Carlos Chiattone, Rosaura Saboya, Jose C. Barros, Jose P. Sarmento-Neto, Jose U. Amigo-Filho, Lilian Piron-Ruiz, Juliana Pereira, Dalton A.F. Chamone
Journal: Blood (2006)
Peroxiredoxins-1 and 2 Affect Proliferation and Survival of Lymphoma Cells
Authors: Malgorzata Firczuk, Anna Trzeciecka, Malgorzata Bajor, Angelika Muchowicz, Radoslaw Zagozdzon, Joanna Barankiewicz, Antoni Domagala, Szymon Klossowski, Agata Malinowska, Justyna Chlebowska, Ryszard Ostaszewski, Jakub Golab, Dominika Nowis
Journal: Blood (2014)
Gemcitabine, Vinorelbine and Pegylated Liposomal Doxorubicin (GVD) in the Treatment of Relapsed or Refractory Hodgkin's Lymphoma - Experience of a Portuguese Center
Authors: Luísa Vilaça Queiroz, Paula Fidalgo, Claudia Moreira, Faustino Ilda, Marcos Pantarotto, Marta Ferreira, Liliana Lombo, Dulcineia Pereira, Idília Pina, Monica Mariano, Ângelo Rodrigues, Ana Espirito Santo, Angelo Martins, Ilidia Moreira, Isabel Oliveira, Margarida Marques, Luísa Viterbo, Nelson Domingues, Jose Mario Mariz
Journal: Blood (2012)
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
Authors: R F Schlenk, P Frech, D Weber, P Brossart, H-A Horst, D Kraemer, G Held, M Ringhoffer, A Burchardt, G Kobbe, K Götze, D Nachbaur, T Fischer, M Lübbert, H R Salih, H Salwender, G Wulf, E Koller, M Wattad, W Fiedler, S Kremers, H Kirchen, B Hertenstein, P Paschka, V I Gaidzik, V Teleanu, M Heuser, F Thol, K Döhner, J Krauter, A Ganser, H Döhner
Journal: Leukemia (2017)

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM)
Authors: Lionel Ades, Fabien Lebras, Marie Sebert, Charikleia Kelaidi, Thierry Lamy, Francois Dreyfus, Jacques Delaunay, Sorin Visanica, Pascal Turlure, Agnes Guerci, Marie Paule Cabrol, Anne Banos, Michel Blanc, Norbert Vey, Virginie Eclache, Sylvie Chevret, Pierre Fenaux
Journal: Blood (2010)
Left Ventricular Contractility and Energetic Cost in Disease Models. An approach from the pressure-volume diagram.
Authors: Yoichi Goto, Shiho Futaki, Osamu Kawaguchi, Katsuya Hata, Toshiyuki Takasago, Akio Saeki, Takehiko Nishioka, Hiroyuki Suga
Journal: Circulation (1992)

Left ventricular contractility and the energetic cost of contraction were assessed in various disease models in experimental animals utilizing frameworks of Emax (left ventricular contractility index) and pressure-volume area (PVA, a measure of total left ventricular mechanical energy expenditure) derived from the pressure-volume (P-V) diagram. Under various  conditions, PVA linearly correlates with myocardial  consumption per beat (VO2) in a load-independent manner. The reciprocal of the slope of the linear VO2-PVA relation indicates contractile  (the energy transduction efficiency from  to total mechanical energy). It was similar between dog and rabbit hearts (about 40%) and was not significantly affected by enhanced contractility with calcium, epinephrine, or cardiac cooling, or by depressed contractility with propranolol, decreased coronary perfusion pressure, or stunned myocardium. However, in thyrotoxic rabbit hearts  efficiency was significantly depressed compared to normal hearts. On the other hand, the VO2 intercept of the VO2-PVA relation (PVA-independent VO2), which reflects VO2 for non-mechanical activities such as excitation-contraction coupling and basal metabolism, positively correlates with Emax. Therefore, the ratio of an increase in PVA-independent VO2 to an increase in Emax indicates oxygen cost of contractility. Oxygen cost of contractility was higher in stunned myocardium than in normal hearts, suggesting that the energy cost of calcium handling is elevated in stunned myocardium. Thus, using the frameworks of Emax and PVA, we can interconnect cardiac mechanics and energetics. Further, using the concepts of  efficiency and  cost of contractility, we can approach the pathogenesis of variously altered  conditions.
Immunoliposomes Incorporated with Humanized Monoclonal Antibody, Milatuzumab, Induce Cell Death in CLL by Retention of the CD74 Receptor On the Surface of B Cells.
Authors: Erin K Hertlein, Georgia Triantafillou, Joshua Hessler, Xiaoli Zhang, David Jarjoura, David M. Lucas, Robert J Lee, Natarajan Muthusamy, David M Goldenberg, John C. Byrd
Journal: Blood (2009)
A new hope for obesity management: Boron inhibits adipogenesis in progenitor cells through the Wnt/β-catenin pathway
Authors: Ayşegül Doğan, Selami Demirci, Hüseyin Apdik, Omer Faruk Bayrak, Sukru Gulluoglu, Emre Can Tuysuz, Oleg Gusev, Albert A. Rizvanov, Emrah Nikerel, Fikrettin Şahin
Journal: Metabolism (2017)
To Treat or Not to Treat: Metabolomics Reveals Biomarkers for Treatment Indication in Chronic Lymphocytic Leukaemia Patients
Authors: Jaroslaw Piszcz, Emily Grace Armitage, Ferrarini Alessia, Francisco Javier Ruperez, Agnieszka Kulczynska, Lukasz Bolkun, Janusz Kloczko, Adam Kretowski, Michal Ciborowski, Coral Barbas
Journal: Blood (2015)
Prophylaxis for Stress Ulcers With Proton Pump Inhibitors Is Not Associated With Increased Risk of Bloodstream Infections in the Intensive Care Unit
Authors: Margot E. Cohen, Joanne M. Hathway, Hojjat Salmasian, Jianfang Liu, Melissa Terry, Julian A. Abrams, Daniel E. Freedberg
Journal: Clinical Gastroenterology and Hepatology (2017)
Characteristics and Prognosis of AML Patients with or without a History of Clonal Hematopoiesis
Authors: Felicitas Thol, Larissa Köhler, Sabrina Klesse, Razif Gabdoulline, Arnold Kloos, Alessandro Liebich, Martin Wichmann, Anuhar Chaturvedi, Jana Fabisch, Verena I. Gaidzik, Peter Paschka, Lars Bullinger, Gesine Bug, Hubert Serve, Gudrun Göhring, Brigitte Schlegelberger, Michael Luebbert, Hartmut H. Kirchner, Mohammad Amen Wattad, Doris Kraemer, Bernd Hertenstein, Gerhard Heil, Walter Fiedler, Juergen Krauter, Richard F. Schlenk, Konstanze Döhner, Hartmut Döhner, Arnold Ganser, Michael Heuser
Journal: Blood (2015)
Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial
Authors: Olivia Meggetto, Elizabeth Maunsell, Rowan Chlebowski, Paul Goss, Dongsheng Tu, Harriet Richardson
Journal: Journal of Clinical Oncology (2017)

Purpose Aromatase inhibitors are established breast cancer chemoprevention interventions. However, nonadherence remains a significant challenge. We investigated the association between worsening menopause-specific quality of life, baseline participant characteristics, and early treatment discontinuation within the Mammary Prevention.3 (MAP.3) breast cancer prevention trial. Methods In the MAP.3 randomized, placebo-controlled trial evaluating exemestane, participants completed the Menopause-Specific Quality of Life Questionnaire (MENQOL) at entry and at 6 months. Multivariable log-binomial regression was used to assess the associations of baseline participant characteristics and clinically meaningful worsening in menopause-specific quality of life (QOL) with treatment discontinuation at 1 year. Results Of the 4,501 participants eligible for this analysis, 724 (17%) discontinued assigned treatment within the first year of random assignment of treatment (19% of the exemestane group and 13% of the placebo group). Between 19% and 35% of women experienced a clinically meaningful worsening in the vasomotor, sexual, physical, and psychosocial domains of the MENQOL within 6 months of treatment initiation. Regardless of receiving exemestane or not, experiencing a worsening in any MENQOL domain or, especially, overall menopause-specific QOL, was associated with early treatment discontinuation (relative risk, 1.79; 95% CI, 1.53 to 2.10 for overall worsening). Assignment to exemestane, having a smoking history, and current employment also were significantly associated with early discontinuation. Conclusion Negative changes in menopause-specific QOL influence a woman’s decision to stop chemoprevention therapy. Attention to such symptoms may improve QOL and potentially improve chemoprevention adherence.
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients
Authors: Ilaria Iacobucci, Anna Ferrari, Annalisa Lonetti, Cristina Papayannidis, Viviana Guadagnuolo, Emanuela Ottaviani, Mariachiara Abbenante, Federica Cattina, Antonella Vitale, Stefania Paolini, Simona Soverini, Sarah Parisi, Francesca Paoloni, Fausto Castagnetti, Marco Vignetti, Robin Foà, Michele Baccarani, Giovanni Martinelli
Journal: Blood (2010)
Prevalence and Prognostic Value of BCL2 and MYC Protein Expression within ABC and GCB Subtypes in Patients with Previously Untreated, Diffuse Large B-Cell Lymphoma: Analysis from the Phase III MAIN Study
Authors: Elizabeth Punnoose, Franklin V. Peale, Guiyuan Lei, Thomas Sandmann, Richard Bourgon, Edith Szafer-Glusman, An Do, Randy D. Gascoyne, Gilles A. Salles, John F. Seymour, Marek Trneny, Laurie H. Sehn, F. Javier Munoz, Kirsten E. Mundt
Journal: Blood (2015)
Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus
Authors: Deepak L. Bhatt, Tilo Grosser, Jing-fei Dong, Douglas Logan, Walter Jeske, Dominick J. Angiolillo, Andrew L. Frelinger, Lanyu Lei, Juan Liang, Jason E. Moore, Byron Cryer, Upendra Marathi
Journal: Journal of the American College of Cardiology (2017)
JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1
Authors: N Gupta, B Edelmann, T M Schnoeder, F C Saalfeld, D Wolleschak, S Kliche, B Schraven, F H Heidel, T Fischer
Journal: Leukemia (2017)

qChIP) assay was performed to directly measure the DNA-binding function. 15 This assay confirmed an absence of DNA-binding affinity to the DNA sequences derived from human PC-HC in the mutated IKAROS protein (Supplementary Figure S3b).On the basis of previous analyses on specific single amino acid substitutions in IKAROS, we are aware that only six amino acid regions (154, 159, 162, 180, 184 and 188) within the second or third N-terminal zinc finger are critical sites for both high-affinity DNA binding and PC-HC localization with regard to IKAROS function. 3 A previous structural study also indicated the importance of amino acid regions and mentioned that the N159 region involves residues for pericentromeric targeting and protein-DNA interactions according to homology models.Consistent with these findings, the IKAROS mutation in our patient was highly damaging to the protein function.The IKAROS mutated sites and accompanying somatic mutations in leukemic cells may contribute to the differences in clinical manifestations, as well as leukemic phenotypes, as was observed in our patient and previously reported patients.In summary, the present case provides the first definitive evidence on the ability of an IKAROS heterozygous mutation to cause both immunodeficiency and NOTCH1-driven T-ALL in humans.
Gene Expression Profiling of Peripheral T-Cell Lymphoma (PTCL, NOS) and Comparison to Diffuse Large B-Cell Lymphoma (DLBCL).
Authors: Daruka Mahadevan, Catherine Spier, Kimiko Della Croce, Susan Miller, Benjamin George, Christopher J. Riley, Stephen Warner, Thomas M. Grogan, Thomas P. Miller
Journal: Blood (2004)
Malignant Plasma Cells Responsible for Multiple Myeloma Relapse Are Detectable and Survive Nine Days After High Dose Melphalan: Highlight of An Optimal Therapeutic Window ?
Authors: Anouk Caraux, Laure Vincent, Jerome Moreaux, Guilhem Requirand, Caroline Bret, Jean-Luc Veyrune, Christophe Duperray, Salahedine Bouhya, Jean-Francois Rossi, Bernard Klein
Journal: Blood (2011)
Dose-Dense Rituximab in Combination with Biweekly CHOP-14 for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Phase-I/II and Pharmacokinetic Study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
Authors: Viola Poeschel, Maike Nickelsen, Mathias Hanel, Stephan Kremers, Swen Wessendorf, Hartmut Eimermacher, Norma Peter, Michael Wenger, Marcel Reiser, Norbert Schmitz, Michael Pfreundschuh
Journal: Blood (2006)
Combined Inhibition of Janus and Aurora Kinases by the Novel Small Molecule Inhibitor AZD1480 Induces Cell Death and Downregulates PD-L1 and PD-L2 Expression In Hodgkin Lymphoma
Authors: Enrico Derenzini, Daniela Buglio, Hiroshi Katayama, Yuan Ji, Subrata Sen, Anas Younes
Journal: Blood (2010)
Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer
Authors: Lakshmi Reddy Bollu, Abhijit Mazumdar, Michelle I. Savage, Powel H. Brown
Journal: Clinical Cancer Research (2017)

Abstract The aberrant activation of oncogenic signaling pathways is a universal phenomenon in cancer and drives tumorigenesis and malignant transformation. This abnormal activation of signaling pathways in cancer is due to the altered expression of protein kinases and phosphatases. In response to extracellular signals, protein kinases activate downstream signaling pathways through a series of protein phosphorylation events, ultimately producing a signal response. Protein tyrosine phosphatases (PTP) are a family of enzymes that hydrolytically remove phosphate groups from proteins. Initially, PTPs were shown to act as tumor suppressor genes by terminating signal responses through the dephosphorylation of oncogenic kinases. More recently, it has become clear that several PTPs overexpressed in human cancers do not suppress tumor growth; instead, they positively regulate signaling pathways and promote tumor development and progression. In this review, we discuss both types of PTPs: those that have tumor suppressor activities as well as those that act as oncogenes. We also discuss the potential of PTP inhibitors for cancer therapy. Clin Cancer Res; 23(9); 2136–42. ©2017 AACR.
Thrombotic Microangiopathy in Patients with Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Seung Ah Yahng, Byung-Sik Cho, Chang-Ki Min, Ki-Seong Eom, Yoo-Jin Kim, Heeje Kim, Seok Lee, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Chun-Choo Kim
Journal: Blood (2008)